3,4-Diaminopyridine

From Self-sufficiency
Revision as of 22:01, 29 August 2010 by Citation bot 1 (Talk) (Citations: [Pu184]Tweaked: doi. You can use this bot yourself. Report bugs here.)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
3,4-Diaminopyridine
120px
Systematic (IUPAC) name
3,4-Diaminopyridine
Clinical data
Routes of
administration		 Oral
Legal status
Legal status
  • Phase III
Pharmacokinetic data
Bioavailability 30% [1],[2]
Identifiers
CAS Number 54-96-6
PubChem CID 5918
ChemSpider 5705
Chemical data
Formula C5H7N3
Molar mass 109.13[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

3,4-Diaminopyridine is an organic compound with the formula C5H3N(NH2)2. It is formally derived from pyridine by substitution of the 3 and 4 positions with an amino group.

Applications

3,4-Diaminopyridine experimental drug for the treatment of Lambert-Eaton Syndrome. In Lambert-Eaton Syndrome, acetylcholine release is inhibited as antibodies meant to target characteristic cancers target Ca2+ channels on the prejunctional membrane instead. 3,4-Diaminopyridine works by blocking potassium channel efflux in nerve terminals so that action potential duration is increased. Ca2+ channels can then be open for longer time and allow greater acetylcholine release to stimulate muscle at end plate. It is also used to treat many of the Congenital Myasthenic Syndromes.

This compound has also been proposed for the treatment of multiple sclerosis.[3]

See also

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />


Stub icon This pharmacology-related article is a stub. You can help ssf by expanding it.
Antiarrhythmic III/delayed rectifier
Other/ungrouped/unknown
fa:۳و۴-دی آمینو پیریدین nl:3,4-diaminopyridine
  1. ↑ AAEM Quality Assurance Committee. American Association of Electrodiagnostic Medicine. (2001). "Practice parameter for repetitive nerve stimulation and single fiber EMG evaluation of adults with suspected myasthena gravis or Lambert-Eaton myasthenic syndrome: summary statement". Muscle Nerve. 24 (9): 1236–1238. doi:10.1002/mus.1139. PMID 11494280. 
  2. ↑ Lundh H, Nilsson O, Rosen I, Johansson S. (1993). "Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome". Acta Neurol Scand. 88 (2): 136–140. doi:10.1111/j.1600-0404.1993.tb04205.x. PMID 8213058. 
  3. ↑ Judge S, Bever C (2006). "Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment". Pharmacol. Ther. 111 (1): 224–59. doi:10.1016/j.pharmthera.2005.10.006. PMID 16472864. 
Retrieved from "http://ssf.f15ijp.com/wiki/index.php?title=3,4-Diaminopyridine&oldid=29168"